Curis Inc. reports third quarter net loss of $7.7 million

Reuters11-07

Curis Inc. reports third quarter net loss of $7.7 million

Curis Inc. reported revenues of $3.2 million for the third quarter of 2025, up from $2.9 million in the same period in 2024, primarily from royalty revenues related to Genentech/Roche's sales of Erivedge. The company reported a net loss of $7.7 million, or $0.49 per share, compared to a net loss of $10.1 million, or $1.70 per share, for the third quarter of 2024. Research and development expenses decreased to $6.4 million from $9.7 million in the prior year period. Cash and cash equivalents totaled $9.1 million as of September 30, 2025, with approximately 12.7 million shares of common stock outstanding. Curis expects its current cash position to fund operations into the first quarter of 2026. The company also announced that initial clinical data from an Investigator Sponsored Study in pancreatic ductal adenocarcinoma will be presented at the ASCO Gastrointestinal Cancers Symposium in January 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE18150) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581121730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581121730","market":"nz","top_or_hot":-1,"title":"Curis Inc. reports third quarter net loss of $7.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Curis Inc. reports third quarter net loss of $7.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Curis Inc. reported revenues of $3.2 million for the third quarter of 2025, up from $2.9 million in the same period in 2024, primarily from royalty revenues related to Genentech/Roche's sales of Erivedge. The company reported a net loss of $7.7 million, or $0.49 per share, compared to a net loss of $10.1 million, or $1.70 per share, for the third quarter of 2024. Research and development expenses decreased to $6.4 million from $9.7 million in the prior year period. Cash and cash equivalents totaled $9.1 million as of September 30, 2025, with approximately 12.7 million shares of common stock outstanding. Curis expects its current cash position to fund operations into the first quarter of 2026. The company also announced that initial clinical data from an Investigator Sponsored Study in pancreatic ductal adenocarcinoma will be presented at the ASCO Gastrointestinal Cancers Symposium in January 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE18150) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Curis Inc. reports third quarter net loss of $7.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCuris Inc. reports third quarter net loss of $7.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Curis Inc. reports third quarter net loss of $7.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Curis Inc. reported revenues of $3.2 million for the third quarter of 2025, up from $2.9 million in the same period in 2024, primarily from royalty revenues related to Genentech/Roche's sales of Erivedge. The company reported a net loss of $7.7 million, or $0.49 per share, compared to a net loss of $10.1 million, or $1.70 per share, for the third quarter of 2024. Research and development expenses decreased to $6.4 million from $9.7 million in the prior year period. Cash and cash equivalents totaled $9.1 million as of September 30, 2025, with approximately 12.7 million shares of common stock outstanding. Curis expects its current cash position to fund operations into the first quarter of 2026. The company also announced that initial clinical data from an Investigator Sponsored Study in pancreatic ductal adenocarcinoma will be presented at the ASCO Gastrointestinal Cancers Symposium in January 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE18150) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRIS","symbol_name":"居里","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbM3KvS:1","article_id":"2581121730","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581121730","pubTimestamp":1762462845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Curis Inc. reported revenues of $3.2 million for the third quarter of 2025, up from $2.9 million in the same period in 2024, primarily from royalty revenues related to Genentech/Roche's sales of Erivedge. The company reported a net loss of $7.7 million, or $0.49 per share, compared to a net loss of $10.1 million, or $1.70 per share, for the third quarter of 2024. Research and development expenses decreased to $6.4 million from $9.7 million in the prior year period. Cash and cash equivalents totaled $9.1 million as of September 30, 2025, with approximately 12.7 million shares of common stock outstanding. Curis expects its current cash position to fund operations into the first quarter of 2026. The company also announced that initial clinical data from an Investigator Sponsored Study in pancreatic ductal adenocarcinoma will be presented at the ASCO Gastrointestinal Cancers Symposium in January 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRIS":"居里","BK4139":"生物科技"},"translate_title":"Curis Inc.报告第三季度净亏损770万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRIS":0.9},"content_text":"Curis Inc. reports third quarter net loss of $7.7 million\n    \n\n        Curis Inc. reported revenues of $3.2 million for the third quarter of 2025, up from $2.9 million in the same period in 2024, primarily from royalty revenues related to Genentech/Roche's sales of Erivedge. The company reported a net loss of $7.7 million, or $0.49 per share, compared to a net loss of $10.1 million, or $1.70 per share, for the third quarter of 2024. Research and development expenses decreased to $6.4 million from $9.7 million in the prior year period. Cash and cash equivalents totaled $9.1 million as of September 30, 2025, with approximately 12.7 million shares of common stock outstanding. Curis expects its current cash position to fund operations into the first quarter of 2026. The company also announced that initial clinical data from an Investigator Sponsored Study in pancreatic ductal adenocarcinoma will be presented at the ASCO Gastrointestinal Cancers Symposium in January 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE18150) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581121730","isCrawlerRequest":true}